RT Journal Article
T1 Dissecting the Brain/Islet Axis in Metabesity.
A1 Fuente-Martin, Esther
A1 Mellado-Gil, Jose M
A1 Cobo-Vuilleumier, Nadia
A1 Martin-Montalvo, Alejandro
A1 Romero-Zerbo, Silvana Y
A1 Diaz-Contreras, Irene
A1 Hmadcha, Abdelkrim
A1 Soria, Bernat
A1 Martin-Bermudo, Francisco
A1 Reyes, Jose C
A1 Bermudez-Silva, Francisco J
A1 Lorenzo, Petra I
A1 Gauthier, Benoit R
K1 T2DM
K1 Astrocytes
K1 Inflammation
K1 Metabesity
K1 Obesity
K1 Pancreatic islet
AB The high prevalence of type 2 diabetes mellitus (T2DM), together with the fact that current treatments are only palliative and do not avoid major secondary complications, reveals the need for novel approaches to treat the cause of this disease. Efforts are currently underway to identify therapeutic targets implicated in either the regeneration or re-differentiation of a functional pancreatic islet β-cell mass to restore insulin levels and normoglycemia. However, T2DM is not only caused by failures in β-cells but also by dysfunctions in the central nervous system (CNS), especially in the hypothalamus and brainstem. Herein, we review the physiological contribution of hypothalamic neuronal and glial populations, particularly astrocytes, in the control of the systemic response that regulates blood glucose levels. The glucosensing capacity of hypothalamic astrocytes, together with their regulation by metabolic hormones, highlights the relevance of these cells in the control of glucose homeostasis. Moreover, the critical role of astrocytes in the response to inflammation, a process associated with obesity and T2DM, further emphasizes the importance of these cells as novel targets to stimulate the CNS in response to metabesity (over-nutrition-derived metabolic dysfunctions). We suggest that novel T2DM therapies should aim at stimulating the CNS astrocytic response, as well as recovering the functional pancreatic β-cell mass. Whether or not a common factor expressed in both cell types can be feasibly targeted is also discussed.
SN 2073-4425
YR 2019
FD 2019-05-08
LK http://hdl.handle.net/10668/13931
UL http://hdl.handle.net/10668/13931
LA en
NO The authors are supported by the Consejería de Salud, Fundación Pública Andaluza Progreso y Salud, Junta de Andalucía (PI-0727-2010 to B.R.G., PI-0085-2013 to P.I.L., PI-0006-2016 to E.F.M., PI-0574-2012 to S.Y.R.Z., and PI-0247-2016 to F.J.B.S.), the Consejería de Economía, Innovación y Ciencia (P10.CTS.6359 to B.R.G.), the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III co-funded by Fondos FEDER (PI10/00871 and PI13/00593 to B.R.G., PI13/00309 and PI17/01004 to F.J.B.S., and BFU2014-5343-P to J.C.R.), Vencer el Cancer (B.R.G), DiabetesCero (B.R.G.), and the Red TerCel program (RD12/0019/0028 to B.S.). E.F.M. is recipient of a Juan de la Cierva Incorporación Fellowship from the Ministerio de Economía y Competitividad (IJCI-2015-26238). S.Y.R.Z. is a recipient of a postdoctoral fellowship from Consejería de Salud, Junta de Andalucía (RH-0070-2013). F.J.B.S. is recipient of a “Nicolás Monardes” research contract from Consejería de Salud Junta de Andalucía, (C-0070-2012). A.M.M. is supported by CP14/00105 and PI18/01590 from the Instituto de Salud Carlos III co-funded by Fondes FEDER. CIBERDEM is an initiative of the Instituto de Salud Carlos III.
DS RISalud
RD Apr 11, 2025